Watch SNTI. Know when insiders buy.
One email the day a filing lands. Free.
SNTI
Senti Biosciences Holdings, Inc.
0.21
−0.02 −6.93%
USD · close Oct 21
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
48
WATCH · shorts 48
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $6.6MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$49.6MNET CASH —52W 0.21 – 2.39SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $17K | — | — | −$14.5M | −$12.8M | — | -0.41 | −$14.2M | — | — | Aug 14 |
| Q1 2026 · Mar 31 | $16K | — | — | −$4.6M | −$4.2M | — | -0.14 | −$7.5M | — | — | Aug 14 |
| Q4 2025 · Dec 31derived | — | — | — | −$18.6M | −$14.5M | — | -0.48 | −$6.9M | $0 | −$6.9M | Mar 27 |
| Q3 2025 · Sep 30 | — | — | — | −$16.9M | −$18.1M | — | -0.69 | −$9.4M | $0 | −$9.4M | Nov 13 |
| Q2 2025 · Jun 30 | $0 | — | — | −$16.8M | −$14.7M | — | -0.56 | −$13.1M | $196K | −$13.3M | Aug 14 |
| Q1 2025 · Mar 31 | $0 | — | — | −$16.4M | −$14.1M | — | -1.41 | −$14.1M | $0 | −$14.1M | Aug 14 |
| Q4 2024 · Dec 31derived | $0 | — | — | −$16.2M | −$610K | — | -0.62 | −$13.5M | $11K | −$13.5M | Mar 27 |
| Q3 2024 · Sep 30 | $0 | −100.0% | — | −$15.2M | −$28.9M | — | -6.31 | −$7.9M | $0 | −$7.9M | Nov 13 |
| Q2 2024 · Jun 30 | $0 | — | — | −$13.4M | −$11.2M | — | -2.45 | −$8.3M | $0 | −$8.3M | Nov 13 |
| Q1 2024 · Mar 31 | $0 | — | — | −$16.3M | −$12.1M | — | -2.65 | −$11.7M | $15K | −$11.7M | Nov 13 |
| Q4 2023 · Dec 31 | $0 | — | — | −$18.7M | −$71.1M | — | -4.19 | −$7M | $4K | −$7M | Mar 20 |
| Q3 2023 · Sep 30 | $338K | — | — | −$43.9M | −$14.9M | — | -3.36 | −$15.4M | $1.9M | −$17.2M | Nov 14 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $22K | — | −$68.8M | −$61.4M | -279263.6% | -2.73 | −$43.4M | $196K | −$43.6M | — | — |
| FY2024 · to Dec 31 | $0 | — | −$61M | −$52.8M | — | -12.03 | −$41.4M | $26K | −$41.4M | — | — |
| FY2023 · to Dec 31 | $2.6M | — | −$92.7M | −$71.1M | -2774.6% | -16.01 | −$52.4M | $12M | −$64.4M | — | — |
| FY2022 · to Dec 31 | $4.3M | — | −$62.1M | −$58.2M | -1358.1% | -2.23 | −$34.9M | $41.4M | −$76.3M | — | — |
| FY2021 · to Dec 31 | $2.8M | — | −$40.4M | −$55.3M | -2003.6% | -19.00 | −$34.6M | $5.5M | −$40.2M | — | — |
Every number comes from Senti Biosciences Holdings, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.